Xenoview
Payments companies reported to CMS as associated with Xenoview. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xenoview, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xenoview
These are the largest totals companies reported as associated with Xenoview. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Chase Hall | Kansas City, KS | Pulmonary Disease | $166,032.75 |
| Joseph Mammarappallil | Durham, NC | Diagnostic Radiology | $15,737.44 |
| Mario Castro | Kansas City, KS | Pulmonary Disease | $6,006.93 |
| Stella Davies | Cincinnati, OH | Pediatric Hematology-Oncology | $5,116.64 |
| Borna Mehrad | Gainesville, FL | Pulmonary Disease | $4,708.58 |
| Surya Bhatt | Bethlehem, PA | Pulmonary Disease | $3,639.76 |
| Jamie Macleod | Charlottesville, VA | Pulmonary Disease | $3,047.20 |
| George Washko | Boston, MA | Pulmonary Disease | $3,000.00 |
| Gerald Klein | Pittsboro, NC | $2,791.25 | |
| Rajat Walia | Phoenix, AZ | Pulmonary Disease | $367.15 |
Prescribed Xenoview?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.